Company Filing History:
1 out of 7 
1 out of 1 Years Active: 2022
Title: Lianjun Liu: Innovator in KRAS Inhibitors
Introduction
Lianjun Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of compounds that target KRAS, a critical protein involved in cancer progression. His innovative work has the potential to improve treatment options for patients suffering from various cancers.
Latest Patents
Lianjun Liu holds a patent for "Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof." This patent describes compounds that possess a structure represented by formula (I). The invention details preparation methods for these compounds and their application as KRAS inhibitors. The compounds exhibit an excellent ability to selectively inhibit KRAS, along with improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.
Career Highlights
Throughout his career, Lianjun Liu has worked with notable companies in the biopharmaceutical sector. He has been associated with Suzhou Zelgen Biopharmaceuticals Co., Ltd. and Shanghai Zelgen Pharmaceutical Technology Co., Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Lianjun Liu has collaborated with several professionals in his field, including Binhua Lv and Dawei Cui. These collaborations have fostered innovation and have been instrumental in the progress of his research and development efforts.
Conclusion
Lianjun Liu is a key figure in the development of KRAS inhibitors, with a focus on enhancing the efficacy and safety of cancer treatments. His contributions to the field of biopharmaceuticals are noteworthy and continue to impact the industry positively.